We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+1.13%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$10.4B
AUM Growth
-$279M
(-2.6%)
Cap. Flow
-$218M
Cap. Flow
% of AUM
-2.1%
Top 10 Holdings %
Top 10 Hldgs %
17.29%
Holding
1,364
New
413
Increased
268
Reduced
302
Closed
358
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$105M |
| 2 |
EMC
EMC CORPORATION
EMC
|
+$103M |
| 3 |
iShares MSCI Emerging Markets ETF
EEM
|
+$97.6M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$77.4M |
| 5 |
Humana
HUM
|
+$71.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$125M |
| 2 |
Perrigo
PRGO
|
+$103M |
| 3 |
AGN
Allergan plc
AGN
|
+$99.6M |
| 4 |
Pfizer
PFE
|
+$90M |
| 5 |
Viatris
VTRS
|
+$88.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 15.63% |
| 2 | Healthcare | 15.57% |
| 3 | Communication Services | 13.26% |
| 4 | Technology | 11.56% |
| 5 | Financials | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Gilead Sciences
GILD
$161B
| $54.2M | 0.52% |
590,025
-274,067
| -32% | -$24.7M |
|
52
AutoZone
AZO
$48.3B
| $52.4M | 0.5% |
65,717
-26,866
| -29% | -$20.3M |
|
53
Cardinal Health
CAH
$53.4B
| $51.7M | 0.5% |
630,446
-50,407
| -7% | -$4.1M |
|
54
MGIC Investment
MTG
$6.27B
| $49.4M | 0.48% |
6,444,296
-2,393,997
| -27% | -$17.1M |
|
55
Affiliated Managers Group
AMG
$9.46B
| $47.2M | 0.45% |
290,700
+282,616
| +3,496% | +$39.4M |
|
56
Criteo
CRTO
$1.03B
| $47M | 0.45% |
1,133,902
-211,313
| -16% | -$7.38M |
|
|
DFS
57
DELISTED
Discover Financial Services
DFS
| $46.9M | 0.45% |
920,772
+310,241
| +51% | +$15M |
|
|
SPR
58
DELISTED
Spirit AeroSystems
SPR
| $46.2M | 0.44% |
1,017,517
+489,685
| +93% | +$22.3M |
|
59
DaVita
DVA
$15.1B
| $44.2M | 0.43% |
603,003
+84,935
| +16% | +$5.74M |
|
60
Mastercard
MA
$477B
| $44.2M | 0.43% |
467,333
-41,024
| -8% | -$3.63M |
|
61
Keurig Dr Pepper
KDP
$40.4B
| $43.2M | 0.42% |
483,528
+404,586
| +513% | +$36.9M |
|
|
GCP
62
DELISTED
GCP Applied Technologies Inc.
GCP
| $42.4M | 0.41% |
+2,126,582
| New | +$38.6M |
|
63
F5
FFIV
$22.1B
| $42.1M | 0.41% |
397,269
-252,307
| -39% | -$24.2M |
|
64
Dollar Tree
DLTR
$23.1B
| $42M | 0.41% |
509,800
+466,669
| +1,082% | +$36.8M |
|
65
Sensient Technologies
SXT
$5.4B
| $41.5M | 0.4% |
653,595
+290,794
| +80% | +$17.1M |
|
66
The Mosaic Company
MOS
$7.09B
| $40.2M | 0.39% |
1,488,819
-124,698
| -8% | -$3.26M |
|
|
BNY
67
Bank of New York Mellon
BNY
$108B
| $39.4M | 0.38% |
+1,069,397
| New | +$38.8M |
|
68
Graphic Packaging
GPK
$3.26B
| $39.1M | 0.38% |
3,043,618
+1,473,632
| +94% | +$17.9M |
|
|
AGN
69
DELISTED
Allergan plc
AGN
| $38.8M | 0.37% |
144,657
-347,854
| -71% | -$99.6M |
|
|
PRAH
70
DELISTED
PRA Health Sciences, Inc.
PRAH
| $38.6M | 0.37% |
902,245
+655,624
| +266% | +$27.7M |
|
|
TWX
71
DELISTED
Time Warner Inc
TWX
| $37.9M | 0.36% |
521,982
+135,692
| +35% | +$9.34M |
|
72
Travelers Companies
TRV
$80.8B
| $37.2M | 0.36% |
318,324
-4,953
| -2% | -$541K |
|
73
Assured Guaranty
AGO
$3.78B
| $36.7M | 0.35% |
1,451,858
-484,875
| -25% | -$11.9M |
|
74
Ulta Beauty
ULTA
$20.4B
| $36.2M | 0.35% |
186,776
+147,484
| +375% | +$25.7M |
|
75
Coca-Cola
KO
$354B
| $35.7M | 0.34% |
769,353
-523,813
| -41% | -$22.8M |
|
Similar funds
Marshall Wace's Q1 2016 Portfolio in Review
As of Q1 2016, Marshall Wace held 1,364 positions worth $10.4B, down 2.6% from $10.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Marshall Wace's Q1 2016 filing shows 413 new, 268 increased, 302 reduced and 358 closed positions. Its largest new stake was iShares MSCI Emerging Markets ETF: 3,149,620 shares worth $108M. The largest sale was Bristol-Myers Squibb, an estimated $125M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 16% of assets, up from 12% a quarter earlier, followed by Healthcare and Communication Services.
- Marshall Wace's largest Q1 2016 buy was iShares MSCI Emerging Markets ETF: 3,149,620 shares worth $108M.
- Marshall Wace added most to Adobe in Q1 2016, an estimated $105M increase.
- Marshall Wace's biggest Q1 2016 reduction was Bristol-Myers Squibb, cutting an estimated $125M.
- Marshall Wace fully exited Perrigo in Q1 2016, selling an estimated $103M.
- Marshall Wace's ten largest holdings make up 17% of its $10.4B portfolio in Q1 2016.
- Marshall Wace opened 413 new positions and closed 358 in Q1 2016.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $10.4B.
Based on Marshall Wace's 13F filing for Q1 2016, filed 13 May 2016.